UB Paderborn / Katalog / Suche / in CDI

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Multiple sclerosis, 2022-03, Vol.28 (3), p.480-486

2022

Link zum Volltext

Verfügbarkeit prüfen

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis

Clinical cancer research, 2015-11, Vol.21 (21), p.4903-4912

2015

Link zum Volltext

Verfügbarkeit prüfen

Quantitative evaluation of all hexamers as exonic splicing elements

Genome research, 2011-08, Vol.21 (8), p.1360

2011

Link zum Volltext

Verfügbarkeit prüfen

miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis

Cancer cell, 2011-07, Vol.20 (1), p.104-118

2011

Link zum Volltext

Verfügbarkeit prüfen

Serum microRNAs as biomarkers for recurrence in melanoma

Journal of translational medicine, 2012-08, Vol.10 (1), p.155-155, Article 155

2012

Link zum Volltext

Verfügbarkeit prüfen

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Frontiers in neurology, 2023-04, Vol.14, p.1099376-1099376

2023

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418795085-1756286418795085

2018

Link zum Volltext

Verfügbarkeit prüfen

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma

PloS one, 2011-09, Vol.6 (9), p.e25264-e25264

2011

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418791143-1756286418791143

2018

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve)

Journal of the American College of Cardiology, 2010-12, Vol.56 (24), p.1984-1993

2010

Link zum Volltext

Verfügbarkeit prüfen

Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population

PloS one, 2012-09, Vol.7 (9), p.e44540-e44540

2012

Link zum Volltext

Verfügbarkeit prüfen

Sample Size Calculation for Controlling False Discovery Proportion

Journal of Probability and Statistics, 2012-01, Vol.2012, p.1-13

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety of eculizumab in NMOSD and MG: Analysis of the phase 3 studies prevent and regain, and their extensions

Journal of the neurological sciences, 2021-10, Vol.429, p.118787, Article 118787

2021

Link zum Volltext

Verfügbarkeit prüfen

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

Annals of neurology, 2021-06, Vol.89 (6), p.1088-1098

2021

Link zum Volltext

Verfügbarkeit prüfen

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

Multiple sclerosis, 2017-01, Vol.23 (1), p.94-105

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder

Journal of the neurological sciences, 2021-10, Vol.429, p.118080, Article 118080

2021

Link zum Volltext

Verfügbarkeit prüfen

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects

British journal of clinical pharmacology, 2016-08, Vol.82 (2), p.380-388

2016

Link zum Volltext

Verfügbarkeit prüfen

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Journal of neurology, 2016-09, Vol.263 (9), p.1778-1787

2016

Link zum Volltext

Verfügbarkeit prüfen

Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week

Multiple sclerosis and related disorders, 2018-05, Vol.22, p.134-138

2018

Link zum Volltext

Verfügbarkeit prüfen

Melanoma risk loci as determinants of melanoma recurrence and survival

Journal of translational medicine, 2013-11, Vol.11 (1), p.279-279, Article 279

2013

Link zum Volltext

Verfügbarkeit prüfen

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

Multiple sclerosis and related disorders, 2021-05, Vol.50, p.102849-102849, Article 102849

2021

Link zum Volltext

Verfügbarkeit prüfen

Genetic variation in immunomodulatory genes as markers of melanoma recurrence-free and overall survival

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.9021-9021

2013

Link zum Volltext

Verfügbarkeit prüfen

Partially linear single index Cox regression model in nested case-control studies

Computational statistics & data analysis, 2013-11, Vol.67, p.199-212

2013

Link zum Volltext

Verfügbarkeit prüfen

The melanoma risk loci as determinants of melanoma prognosis

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8557-8557

2012

Link zum Volltext

Verfügbarkeit prüfen

Early alterations of microRNA expression to predict and modulate melanoma metastasis

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8550-8550

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis

Quantitative evaluation of all hexamers as exonic splicing elements

miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis

Serum microRNAs as biomarkers for recurrence in melanoma

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve)

Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population

Sample Size Calculation for Controlling False Discovery Proportion

Safety of eculizumab in NMOSD and MG: Analysis of the phase 3 studies prevent and regain, and their extensions

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week

Melanoma risk loci as determinants of melanoma recurrence and survival

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

Genetic variation in immunomodulatory genes as markers of melanoma recurrence-free and overall survival

Partially linear single index Cox regression model in nested case-control studies

The melanoma risk loci as determinants of melanoma prognosis

Early alterations of microRNA expression to predict and modulate melanoma metastasis

Suchergebnisse filtern